ALPS Medical Breakthroughs ETF (SBIO)
With net assets of $168.21 million, this is the smallest and riskiest (but the most exciting) of our three biotech ETFs.
The fund seeks results that correspond to the performance of its underlying index, the Poliwogg Medical Breakthroughs Index, which is comprised of small- and mid-cap stocks of biotech and pharmaceutical companies that have one or more drugs in either Phase II or Phase III FDA clinical trials.
The fund's holdings include the biotech sector's most entrepreneurial pioneers. They have a market cap of not below $200 million and not above $5 billion. The earlier-stage firms in SBIO devoted about 2.7% of market cap on research and development, 29% higher than the R&D spent by components of the NASDAQ Biotech index.
SBIO has posted a bear-killing gain YTD of 27.86%, compared to the S&P 500's meager gain of 1.25%.
Top holdings include Seattle Genetics, Dyax, Anacor Pharmaceuticals, Neurocrine Biosciences, and Ultragenyx Pharmaceutical.
Expense ratio: 0.50%.
We've found a small-cap biotech "rocket stock" that's about to take off. UCLA researchers are stunned by a Nobel Prize-winning cancer breakthrough that's proven in clinical trials to eliminate lethal forms of cancer with a single dose. One small company owns the patent to this life-saving treatment. Now trading at about $5 a share, the stock of this biotech innovator is projected to surge 2,700% on an imminent FDA announcement. Learn the details now, before the regulatory decision happens. To download the full report, click here.